Compare ARKO & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARKO | MRVI |
|---|---|---|
| Founded | 1970 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.7M | 472.8M |
| IPO Year | N/A | 2020 |
| Metric | ARKO | MRVI |
|---|---|---|
| Price | $6.41 | $3.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $7.50 | $4.57 |
| AVG Volume (30 Days) | 498.5K | ★ 1.1M |
| Earning Date | 02-27-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $7,887,822,000.00 | $192,435,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.00 |
| P/E Ratio | $58.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.51 | $1.67 |
| 52 Week High | $7.84 | $4.77 |
| Indicator | ARKO | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 71.77 | 34.64 |
| Support Level | $5.03 | $3.06 |
| Resistance Level | $6.71 | $3.21 |
| Average True Range (ATR) | 0.24 | 0.17 |
| MACD | 0.09 | -0.06 |
| Stochastic Oscillator | 77.61 | 8.43 |
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.